Double-blind, randomized comparison of the antiemetic efficacy of intravenous dolasetron mesylate and intravenous ondansetron in the prevention of acute cisplatin-induced emesis in patients with cancer. Dolasetron Comparative Chemotherapy-induced Emesis Prevention Group.

@article{Hesketh1996DoubleblindRC,
  title={Double-blind, randomized comparison of the antiemetic efficacy of intravenous dolasetron mesylate and intravenous ondansetron in the prevention of acute cisplatin-induced emesis in patients with cancer. Dolasetron Comparative Chemotherapy-induced Emesis Prevention Group.},
  author={Paul Joseph Hesketh and Rudolph M. Navari and Thomas H. Grote and Richard J. Gralla and John D Hainsworth and M. H. Seitz Kris and L. E. Anthony and Ali Khojasteh and Efstathios Tapazoglou and Claude R. Benedict and William F. Hahne},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={1996},
  volume={14 8},
  pages={2242-9}
}
PURPOSE To assess the comparative antiemetic efficacy of single-dose intravenous (IV) dolasetron mesylate and ondansetron in preventing cisplatin-induced nausea and vomiting. PATIENTS AND METHODS Cancer patients (n = 609) receiving first-course cisplatin chemotherapy were randomized to one of three treatments: 1.8 or 2.4 mg/kg dolasetron mesylate salt (equivalent to 1.3 and 1.8 mg/kg dolasetron base, respectively) or 32 mg ondansetron. Each treatment was infused over 15 minutes, 30 minutes… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 49 extracted citations

Similar Papers

Loading similar papers…